19 Jul AviadoBio
Posted at 18:35h
in
Lisa Deschamps, CEO
Oct. 5 | 3:00pm | FLW Ballroom F
London, UK
(Private)
AviadoBio is relentlessly chasing cures by developing and translating groundbreaking science and precision delivery into potentially life-changing medicines across neurodegenerative diseases. Powered by a precision approach built on three integrated levels — payload, target, and delivery — the company is advancing a pipeline of targeted, one-time AAV gene therapies across frontotemporal dementia with GRN mutations (FTD-GRN), retinitis pigmentosa (RP) and other retinal degenerative diseases,